Huge Unmet Insulin Demand Attracts Drug Makers to China

Diabetes has become a common household in disease in China over the past two decades. In fact, the prevalence of diabetes in China increased from 1% per capita in 1980 to over 12% per capita by 2013. Data reveals that diabetes is about to reach catastrophic levels in the near future.


Though this figure is unexpectedly high, it also has some direct impact on the Chinese diabetes care market. For instance, the consumption of insulin is expected to gain a rapid momentum. The insulin market in China showcased a growth rate at a CAGR of 18.3% during 2008-2013. This indicates tremendous growth opportunities for both local Chinese drug manufacturers and international drug makers. With such a huge need for proper diabetes care, the first step is to fulfill the unmet insulin needs, the basis for diabetes treatment. While multinational companies continue to focus on urban China, the local producers are better positioned to promote insulin products in the rural areas by building better relationships with healthcare professionals.


This growing need for diabetes treatment in China has attracted several leading players from across the globe. Companies such as Novo Nordisk, Eli Lilly and Sanofi Aventis capture a large proportion of the market, whereas domestic players including TonghuaDongbao and Shanghai Fosun Pharmaceutical share a small fraction of the Chinese insulin market.

Talking in terms of latest developments, multinational Sanfoi has announced plans of setting up joint venture with Zhejiang Hisun Pharmaceutical Co. Ltd. for developing insulin and other diabetes related treatments. Other international giants like Eli Lilly and Novo Nordisk have also announced plans for developing close ties with government’s healthcare workers for educating about diabetes. In terms of a long term perspective, the government has also collaborated with several of these leading insulin companies for spreading awareness via campaigns and free diagnostic services.


The government has awakened and taking rational steps to provide better access to medical treatment. Not only is it increasing awareness in the rural areas, but it is also urging both multinational and domestic producers to focus on the production of insulin which is the first step in meeting the needs of a largely diabetic population. Medical insurance, drug supply security, medical-service provision and public health services are some of the initiatives undertaken by the government. The drug manufacturing firms are also carrying out extensive R&D within China to understand the local trends and supplying corresponding solutions to meet future demand.

Contact: Ken Research. Ankur Gupta, Head Marketing & Communications / 1244230204

Leave a Reply

Your email address will not be published. Required fields are marked *

PS PHPCaptcha WP

You may also like:

Infrastructure Linux Software Startup Technology World

Quantum Computing & Future of Cloud Encryption – Upscale Cyber Humanoids!

Conventional computing is based on a bit that can be either a 1 or a 0, representing a single value in a computation. But quantum computing is based on qubits, which simultaneously represent both zero and one values.

Read More
Banking / Finance Retail Software Startup Technology

Secure Payment Gateways and Ecommerce Transactions

This set of security protocols is known is PCI DSS, which stands for Payment Card Industry Data Security and Standard. It ensures to protect the customer data from any online frauds.

Read More
Infrastructure Lifestyle People Software Technology Telecom World

John Perry Barlow, Internet Pioneer, 1947-2018

Internet into “a world that all may enter without privilege or prejudice accorded by race, economic power, military force, or station of birth . . . a world where anyone, anywhere may express his or her beliefs, no matter how singular, without fear of being coerced into silence or conformity.” Those dreams are systematically shattered now.

Read More